Linked Life Data

11939136

Source:http://linkedlifedata.com/resource/pubmed/id/11939136

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2002-4-8
pubmed:abstractText
Pharmacogenomics promises to offer distinct strategic advantages to pharmaceutical companies, physicians, providers and patients. Cambridge Healthtech Institute's 2nd Annual Conference on 'Pharmacogenomics Europe: Presaging Profits' covered all aspects of pharmacogenomics and gave scientists from both academia and from pharmaceutical and biotech companies a great opportunity to discuss the latest progress in pharmacogenomic research. The meeting considered technologies for single nucleotide polymorphism (SNP) screening and expression profiling, bioinformatic tools for data evaluation and gave an overview on the state of affairs and novel approaches to implement pharmacogenomics and pharmacogenetics into drug development and medical treatment. The major strength of the meeting was the merging of scientists from many different disciplines, such as clinicians, pharmacologists, molecular biologists, engineers and bioinformatics experts, into one meeting.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1462-2416
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
303-5
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Cambridge Healthtech Institute's 2nd Annual Conference on Pharmacogenomics Europe: presaging profits.
pubmed:affiliation
Epidauros Biotechnologie AG, Am Neuland, Bernried, Germany.
pubmed:publicationType
Journal Article